News and reflections from the world of AI

    April 20, 2022

    Aiforia expands its portfolio of CE-IVD marked clinical pathology solutions with new AI model for breast cancer diagnostics

    Aiforia Technologies Plc, Press Release, 20 April, 2022 at 09.30 a.m. EEST. Aiforia Technologies Plc announces the CE-IVD marking of the Aiforia® Clinical AI Model for Breast Cancer; ER. Adding to its repertoire of CE-IVD marked clinical AI models for cancer diagnostics, the new AI model automates the calculation of estrogen receptors (ER) — a group of proteins present in the majority of breast ...
    Written by Aiforia
    April 8, 2022

    Employee Spotlight: Interview with Ville Lehtonen

    How long have you been at Aiforia, and what do you do? I joined Aiforia in mid-January 2022 so I've now been an Aiforian for almost 2 months. I'm working as the team lead in our integrations team, meaning that I'm responsible for a little bit of everything. My responsibilities include e.g. coordinating the team, meeting with clients, handling different administrative tasks, agile project ...
    Written by Aiforia
    April 7, 2022

    Benefits of AI in preclinical studies

    The preclinical phase of drug discovery involves extensive safety evaluations of the potential therapeutic intervention, often using cell and animal models of disease. These studies commonly include going through numerous histopathological samples. This contributes to the drug development process being time-consuming and labor-intensive for pharmaceutical and contract research organizations.
    Written by Aiforia
    March 17, 2022

    AI-assisted image analysis of neurodegenerative disease markers

    Introduction Alzheimer’s disease (AD) is the most common cause of dementia, attributed to its characteristic symptoms of brain shrinkage and cell death. Onset of the diseases is thought to be due to abnormal buildup of amyloid-β (Aβ), a protein in the brain, creating plaques and leading to neurodegeneration. Similarly, Aβ buildup can cause cerebral amyloid angiopathy (CAA), a condition which ...
    Written by Aiforia
    February 24, 2022

    Christina Caira reflects on use of AI in Parkinson’s disease research

    Introduction Parkinson’s disease (PD) is the second most common neurodegenerative disorder, characterized by the degeneration of dopamine releasing regions in the brain. The loss of dopamine leads to a chronic and progressive decrease in movement, coordination, and cognition. While there is no cure, an early diagnosis promotes treatment efficacy and prolongs a higher quality of life
    Written by Aiforia
    February 15, 2022

    Aiforia signs agreement with South Korean biotech company to augment its novel drug discovery platform with AI

    The two companies announced an agreement to add Aiforia’s artificial intelligence technology to Genuv’s ATRIVIEW® proprietary drug discovery platform, used to screen both existing drugs and new substances for neuroprotective and neuroregenerative effects. ATRIVIEW® was used to discover Genuv’s leading drug candidate, SNR1611, which has shown the ability to restore CNS function in preclinical ...
    Written by Aiforia
    1 2 3 4 5